Raised plasma concentrations of platelet factor 4 (PF4) in Crohn's disease.

Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease

“…[35] Previous studies explored the course of PF4 in IBD patients, but the results are conflicting. [16,17,36] Moreover, these studies included small numbers of patients, and none of them systematically explored the relationship between serum PF4 and disease activity.…”

“…Platelet factor 4 (PF4) belongs to the CXCL chemokine family with anti-heparin activity and is released from platelet a-granules when platelet activation occurs. [16] Dating back to 1987, Simi et al [17] demonstrated that plasma PF4 levels were significantly higher in CD patients compared with that in healthy volunteers, but they failed to find a correlation between PF4 levels and disease activity. Recently, Takeyama et al [18] showed that PF4 levels were highly correlated with the Crohn Disease Activity Index (CDAI) in CD patients with low CRP levels.…”

Thromboembolism in inflammatory bowel disease: role of platelets.

“…Platelets have received less attention, which is surprising considering the essential role they play in normal haemostasis and the contribution they make to normal coagulation and fibrinolysis. Although abnormalities have been described,22 24 studies have generally been small and inconclusive.…”

Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot study

“…It could be part of a complex mechanism of control of tissue healing and infiltration also involving Matrix Metallo-Proteinases (MMP-2 and 9), highlighted in a recent study addressing as well the characterization of infliximab's mode of action in CD [17]. PF4 is also considered as an acute phase reactant because its level increases with general inflammation, as already observed in plasma of CD patients [18][19][20]. In this study, PF4 level detected on SELDI spectra at m/z 3892 (2H+) was higher for non responders than for the patients responding to infliximab therapy (both before and after treatment).…”